Opinion|Videos|June 5, 2024
SunRISe-1 and NURE-COMBO: Addressing Unmet Needs and Expanding Treatment Options for Bladder Cancer
Author(s)Neal Shore, MD
Neal Shore, MD, FACS, discusses how the SunRISe-1 trial design addresses the need for bladder-sparing treatment options for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer (HR NMIBC) who are ineligible for or refuse radical cystectomy. He also contrasts the treatment approach and outcomes observed in the NURE-COMBO trial with the current standard neoadjuvant chemotherapy plus radical cystectomy regimen for muscle-invasive bladder cancer (MIBC), discussing how this chemoimmunotherapy combination may potentially expand treatment options for this patient population.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- How does the SunRISe-1 trial design address the need for bladder-sparing treatment options for patients with BCG-unresponsive HR NMIBC who are ineligible or refuse radical cystectomy? Discuss the rationale for investigating the combination of TAR-200 and cetrelimab, as well as the TAR-200 and cetrelimab monotherapy approaches, in this patient population and how the preliminary results from the combination cohort compare to the monotherapy cohorts.
- Contrast the treatment approach and outcomes observed in the NURE-COMBO trial with the current standard neoadjuvant chemotherapy plus radical cystectomy regimen for MIBC. How might this chemoimmunotherapy combination potentially expand treatment options for this patient population?
Advertisement
Related to this article
A systematic review and meta-analysis found GLP-1 RAs improved liver and metabolic markers in MASLD and MASH, but long-term benefits remain unproven.
Mailed fecal immunochemical test (FIT) outreach raised CRC screening at federally qualified health centers, but gains faded by year 3.
SIRVA was rare after COVID-19 and flu shots, but COVID-19 vaccination had about 7 more cases per 100,000 doses in a study of 1.8 million.
Mucus plugs on chest CT may signal higher COPD hospitalization and death risk even without cough, and early data suggest they can be treated.
Antimicrobial resistance in bronchiectasis and cystic fibrosis varied widely in a study spanning 11 centers on 3 continents.
Experts break down the GOLD 2026 COPD guidelines, highlighting updates to diagnosis criteria, Group E risk categories, and nonpharmacologic interventions.
An economic evaluation found nontargeted hepatitis C screening in emergency departments offered the greatest health benefit at a cost-effective price.
Naim Alkhouri, MD, on when to judge MASH treatment response, counseling on weight and muscle loss, primary care screening, and future trial end points.
Advertisement
Advertisement
Trending on AJMC
1
EEOC Reportedly Plans to Narrow Pregnancy Accommodation Rules
2
How the GOLD 2026 Guidelines Updated COPD Diagnosis and Treatment
3
CF, Bronchiectasis Antimicrobial Resistance Varies Widely by Region
4
Medicaid Cuts and Caregiving in Congress: Andy Kim
5